Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi (lecanemab-irmb) after the US Food and Drug Administration (FDA) ...
US-based Normunity has raised $75m in a Series B funding round to support the clinical development of its lead programme, NRM-823, a potential first-in-class T-cell engager (TCE) targeting solid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback